Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decipher Labs's EBIT per Share for the
three
months ended in Mar. 2026 was ₹0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-3.82.
During the past 3 years, the average EBIT per Share Growth Rate was -20.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Decipher Labs's EBIT per Share or its related term are showing as below:
BOM:524752'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -20.7 Med: 12 Max: 174.1
Current: -20.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Decipher Labs was 174.10% per year. The lowest was -20.70% per year. And the median was 12.00% per year.
BOM:524752's 3-Year EBIT Growth Rate is ranked worse than 84.98% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs BOM:524752: -20.70
Decipher Labs's EBIT for the
three
months ended in Mar. 2026 was ₹0.8 Mil.
Decipher Labs (BOM:524752) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Decipher Labs EBIT per Share Related Terms
Decipher Labs EBIT per Share Historical Data
* Premium members only.
The historical data trend for Decipher Labs's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decipher Labs (BOM:524752) has a EBIT per Share of ₹-3.82 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Decipher Labs and its competitors. According to the industry distribution chart, Decipher Labs ranks #690 out of 812 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Decipher Labs' EBIT per Share too high?
Decipher Labs' current EBIT per Share is ₹-3.82. Based on the distribution chart, Decipher Labs ranks #690 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Decipher Labs has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Decipher Labs' EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Decipher Labs ranks #690 out of 812 companies for EBIT per Share. This places Decipher Labs in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Decipher Labs and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decipher Labs's current EBIT per Share is ₹-3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decipher Labs stock overvalued right now?
Based on GuruFocus' analysis, Decipher Labs (BOM:524752) is currently considered Fairly Valued. The stock's GF Value™ is ₹6.31, compared to a current price of ₹5.92 — trading 6.2% below its estimated fair value. The current EBIT per Share is ₹-3.82. Decipher Labs' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Decipher Labs (BOM:524752), the current EBIT per Share is ₹-3.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Decipher Labs (BOM:524752) Overvalued in 2026?
Based on GuruFocus' analysis, Decipher Labs stock appears to be undervalued.
The current stock price of ₹5.92 is trading 6.2% below its estimated GF Value™ of ₹6.31.
GuruFocus considers Decipher Labs to be Fairly Valued.
Key valuation signals for BOM:524752:
EBIT per Share: ₹-3.82
GF Value™: ₹6.31 vs. price of ₹5.92 (6.2% below fair value)
No single metric tells the full story. See the BOM:524752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Decipher Labs Ltd deals in the trading and manufacturing of Pharmaceutical drugs and allied products and services, and also offers services and key solutions in the Information Technology industry. It is involved in the manufacturing and marketing of its branded pharmaceutical products, and also provides drug development and manufacturing services to various formulators, manufacturers, and Research and Development agencies for their bulk needs. The group's IT Consultancy offerings include Technology Integration and Systems Consulting, Software Development Consulting, and Management of IT projects. Its reportable operating segments are: Pharmaceutical, which generates the maximum revenue, and IT Consultancy Services. Geographically, the group derives its key revenue from India.
58GF Score
Get the complete analysis for BOM:524752
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524752 has been successfully added to your 
